melatonin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“During the study, serum hs-CRP levels decreased in the melatonin group, and this reduction was significant in comparison with the placebo group ( P = 0.04).”
Quoted verbatim from Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.. - Study
- RCT
- Dose
- Melatonin 5 mg tablet, one tablet nightly one hour before bedtime, for 10 weeks
- Population
- Adults aged 19-75 with chronic kidney failure on continuous ambulatory peritoneal dialysis, four PD centres in Iran; 46 recruited, 44 analysed (22 melatonin, 22 placebo) after one exclusion per group for peritonitis; serum hs-CRP was a pre-specified PRIMARY outcome and the variable the trial was powered on; double-blind, placebo-controlled; hs-CRP by ELISA (ZellBio GmbH), intra-assay CV 5.1%; between-group comparison of change from baseline at week 10
Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.2025PMID:41125682Industry fundedPermalink
Keep reading
- Everything the graph holds on melatonin
- Every compound studied against C-reactive protein concentration
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M3R2JN0GKN6HP82M38SD1SSX